Skip to main content
Top

06-12-2019 | Linagliptin | ADA 2019 | Article

Clinical takeaway: The CAROLINA trial

print
PRINT
insite
SEARCH

John Wilding outlines the key take-home message from the CAROLINA trial comparing the cardiovascular risk profile of the dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride (0:37).

print
PRINT

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »